



5th International Symposium on Hepatitis Care in Substance Users • Oslo • 7 - 9 September 2016 • www.inhsu2016.com

07/09/2016 Epidemiology and Public Health

8:00 am	Registration Foyer
9:00 am - 9:10 am	Welcome to the Conference Scandinavia Ballroom Olav Dalgard, Akershus University Hospital, Norway
9:10 am - 9:15 am	Opening Statement from Community Member Scandinavia Ballroom Ronny Bjørnstad, proLAR, Norway
9:15 am - 10:40 am	Session A: HCV Epidemiology Scandinavia Ballroom Chairperson: Magdalena Harris, London School of Hygiene and Tropical Medicine Chairperson: Tom Hemming Karlsen, University of Oslo
9:15 am - 9:35 am	The Burden of HCV Infection Among PWID Scandinavia Ballroom Sharon Hutchinson, Glasgow Caledonian University, United Kingdom

[Abstract](#)

Presentation

9:35 am - 9:55 am	The Natural History of HCV Infection Scandinavia Ballroom Knut Boe Kielland, Innlandet Hospital Trust, Norway
-------------------	--

[Abstract](#)

[Presentation](#)

9:55 am - 10:10 am

Can Health Risk Behaviours Explain the High Mortality Rate for Adults with Chronic Hepatitis C in the United States?

Scandinavia Ballroom

Hamish Innes, Glasgow caledonian university

[Abstract](#)

[Presentation](#)

10:10 am - 10:25 am

Effect of Combined Harm Reduction Strategies on HCV Primary and Reinfection Incidences among People Who Inject Drugs in Montreal, Canada

Scandinavia Ballroom

Julie Bruneau, Université de Montréal

[Abstract](#)

10:25 am - 10:40 am

The Prison Economy of Needles and Syringes: What Opportunities Exist for Hepatitis C Risk Reduction When Prices are so High?

Scandinavia Ballroom

Andrew Lloyd, University of New South Wales, Australia

[Abstract](#)

[Presentation](#)



10:40 am - 11:00 am

Coffee Break

Foyer

11:00 am - 12:00 pm

Session B: Harm Reduction

Scandinavia Ballroom

Chairperson: Ronny Bjørnstad, proLAR, Norway

Chairperson: Matthew Hickman, University of Bristol, United Kingdom

11:00 am - 11:20 am

State-of-the-Art Lecture: Opioid and Stimulant Substitution Treatment

Scandinavia Ballroom

Johan Franck, Karolinska Institutet, Sweden

[Abstract](#)

[Presentation](#)

11:20 am - 11:40 am

Sharing of Needles, Syringes and Injecting Equipment: Risk of HCV Transmission and Prevention Potential

Scandinavia Ballroom

Holly Hagan, New York University, United States

[Abstract](#)

11:40 am - 12:00 pm

Advances and Opportunities for Harm Reduction in Europe

Scandinavia Ballroom

Mags Maher, EuroNPUD, United Kingdom

[Abstract](#)

[Presentation](#)

12:00 pm - 1:30 pm	Lunch Restaurant	
12:15 pm - 1:15 pm	Industry Sponsored Symposium Stockholm/Oslo	
1:45 pm - 3:00 pm	Session C Oral Abstracts: Epidemiology and Public Health København Chairperson: Peter Vickerman, University of Bristol, United Kingdom Chairperson: Angella Duvnjak, AIVL, Australia	Session D: Oral Abstracts: Epidemiology and Public Health Stockholm/Oslo Chairperson: Lisa Maher, The Kirby Institute, UNSW Australia
1:45 pm - 2:00 pm	Hepatitis C and HIV Treatment Cascades among People Who Inject Drugs. Results from a Sero-Behavioural Survey among Current Injectors in Germany København Ruth Zimmermann, Robert Koch Institute	Molecular Epidemiology of Full-Length Hepatitis C Virus Genomes among Injecting Drug Users with Recent Infection: The Inc3 Study Stockholm/Oslo Chaturaka Rodrigo, University of New South Wales

[Abstract](#)

[Abstract](#)

[Presentation](#)

[Presentation](#)

2:00 pm - 2:15 pm	The Role of Incarceration in HCV Transmission amongst People who Inject Drugs: A Modelling Analysis København Jack Stone, University of Bristol	Liver Disease Burden and Clinical Follow-Up during a Liver Health Promotion Intervention Integrating Non-Invasive Liver Disease Screening in Drug and Alcohol Settings: The Liverlife Study Stockholm/Oslo
-------------------	--	--

Jason Grebely, Kirby Institute, UNSW Australia

[Abstract](#)

[Abstract](#)

[Presentation](#)

[Presentation](#)

2:15 pm - 2:30 pm

Stable Incidence of Hepatitis C Virus Infection among People with a History of Injecting Drug Use in an Australian Prison Setting: The HITS-P Study

København

Evan Cunningham, UNSW Australia

Successful Model of Testing and Linking People who Inject Drugs (PWID) to Treatment using Direct Acting Antivirals

Stockholm/Oslo

Nalinikanta Rajkumar, Community Network for Empowerment (CoNE)

[Abstract](#)

[Abstract](#)

[Presentation](#)

2:30 pm - 2:45 pm

Hepatitis C Virus Exposure, Infection and Associated Risk Behaviours in Two Maximum-Security Prisons in New South Wales, Australia

København

Behzad Hajari, The Kirby Institute, UNSW Australia

Changes in Risk Behaviours during and Following Treatment for Hepatitis C Virus Infection among People Who Inject Drugs: The ACTIVATE Study

Stockholm/Oslo

Håvard Midgard, Akershus University Hospital

[Abstract](#)

[Abstract](#)

[Presentation](#)

[Presentation](#)

2:45 pm - 2:50 pm

Monitoring HCV among People Who Inject Drugs in Europe: A Set of Indicators to Serve Policy and Practice

København

Isabelle Giraudon, EMCDDA

Exposure to opioid substitution therapy following hepatitis C notification: Implications for provision of antiviral therapies in drug treatment settings

Stockholm/Oslo

[Abstract](#)

[Presentation](#)

2:50 pm - 2:55 pm

Combining the Expansion of Medicated Assisted Therapies and HCV Treatment among PWID in Ukraine: Insights from Network Modeling

København

Alexei Zelenev, Yale School of Medicine

[Abstract](#)

2:55 pm - 3:00 pm

HCV Infection and HIV-HCV Coinfection among "New" Injectors during an HIV Outbreak in Athens, Greece: Results from the Aristotle Programme

København

Vana Sypsa, National and Kapodestrian University of Athens

[Abstract](#)

[Presentation](#)

3:00 pm - 3:30 pm

Coffee Break

Sarah Larney, National Drug and Alcohol Research Centre, UNSW Australia

[Abstract](#)

[Presentation](#)

Fatigue in Patients with Chronic Hepatitis C: The FAT-HEP Study. A Cross Sectional Study of Fatigue and its Relation to Substance Use and OST

Stockholm/Oslo

Anne Øvrehus, University of Southern Denmark, Denmark

[Abstract](#)

[Presentation](#)

Multi-Disciplinary Managed Care Networks-Lifesaving Interventions for Hepatitis C Patients

Stockholm/Oslo

John Dillon, University of Dundee

[Abstract](#)

[Presentation](#)

Foyer

3:30 pm - 3:45 pm

Poster Highlights

Scandinavia Ballroom

Jason Grebely, The Kirby Institute, UNSW, Australia

3:45 pm - 5:00 pm

Session E: Limiting the HCV Epidemic

Scandinavia Ballroom

Chairperson: Kimberly Page, University of New Mexico Health Sciences Center, United States

Chairperson: Mary Harrod, CEO, NUAA

3:45 pm - 4:05 pm

State-of-the-Art Lecture: HCV Treatment as Prevention

Scandinavia Ballroom

Matthew Hickman, University of Bristol, United Kingdom

[Presentation](#)

4: 05 pm - 4:25 pm

HCV Vaccine Development: Where Do We Stand?

Scandinavia Ballroom

Andrea Cox, John Hopkins University, United States

[Abstract](#)

[Presentation](#)

4:25 pm - 4:45 pm

The Ebola Vaccine Experience: Cluster Randomisation and Implications for HCV Trial Design

Scandinavia Ballroom

John-Arne Røttingen, Norwegian Institute of Public Health, Norway

Presentation

4:45 pm - 5:00 pm **Liver Or Die: A Peer Training Manual**
Scandinavia Ballroom
Saga Rönnlund, Peer-educator for Liver or Die , The Swedish Drug Users Union

Abstract

5:00 pm - 6:30 pm **Welcome Reception & Poster Viewing Session**
Foyer

6:30 pm **End of Conference Day 1**
Scandinavia Ballroom

08/09/2016 Treatment and Care

9:00 am - 10:30 am **Session F: HCV Treatment Among PWID**
Scandinavia Ballroom
Chairperson: Mags Maher, EuroNPUD, United Kingdom
Chairperson: Julie Bruneau, Université de Montréal

9:00 am - 9:20 am **State-of-the-Art Lecture: Treatment of HCV Infection in 2016**
Scandinavia Ballroom
Graham Foster, University of London, United Kingdom

- [Presentation](#)
9:20 am - 9:40 am **HCV Treatment Trials Among PWID**
Scandinavia Ballroom
Gregory Dore, The Kirby Institute, UNSW, Australia
- 9:40 am - 9:55 am **Community Supported HCV Treatment Model in Provision of Care for PWID in Ukraine**
Scandinavia Ballroom
Sergii Filippovych, Treatment, Procurement and Supply management in Alliance for Public Health

[Abstract](#)

- [Presentation](#)
9:55 am - 10:10 am **C-EDGE CO-STAR: Risk of Reinfection Following Successful Therapy with Elbasvir (EBR) And Grazoprevir (GZR) in Persons Who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT)**
Scandinavia Ballroom
Olav Dalgard, Akershus University Hospital

[Abstract](#)

- [Presentation](#)
10:10 am - 10:25 am **"I got my life back!" - Patients' experiences on being cured for hepatitis C. A qualitative study of fatigue and everyday life in a group of Danish patients.**
Oslo
Nanette Braae Jensen, Department of Infectious Diseases, Odense University Hospital

[Abstract](#)

- [Presentation](#)

- 10:25 am - 11:00 am **Coffee Break**

Foyer

11:00 am - 12:00 pm

Session G: Living with HCV Infection

Scandinavia Ballroom

Chairperson: Jude Byrne, The Australian Injecting and Illicit Drug users League

Chairperson: Phillip Bruggmann

11:00 am - 11:10 am

Extrahepatic Manifestations of HCV Infection: Does HCV Cause Fatigue?

Scandinavia Ballroom

Olav Dalgard, Akershus University Hospital, Norway

[Presentation](#)

11:10 am - 11:20 am

The Patient Perspective

Scandinavia Ballroom

Andi Hüttenmoser, Switzerland

11:20 am - 11:30 am

"But a spoon is not equipment": Risk Behaviour and Knowledge Seeking Among HCV-infected PWID

Scandinavia Ballroom

Aleksandra Bartoszko, Oslo and Akershus University College of Applied Social Sciences

[Abstract](#)

[Presentation](#)

11:30 am - 12:00 pm

Panel Debate: Should HCV treatment be prioritized for people with on-going injecting drug use?

Scandinavia Ballroom

Anne Øvrehus, University of Southern Denmark, Denmark

Martin Kåberg, Karolinska Institutet, Sweden

Sharon Hutchinson, Glasgow Caledonian University, United Kingdom

Peer Brehm Christensen, University of Southern Denmark, Denmark

Moderator: Graham Foster, University of London, United Kingdom

12:00 pm - 1:30 pm

Lunch

	Restaurant	
12:15 pm - 1:15 pm	Industry Sponsored Symposium Stockholm/Oslo	
1:45 pm - 3:00 pm	Session H: Oral Abstracts: Clinical København Chairperson: Georgios Zarkotos, Greek Drug Users Union, Greece Chairperson: Brian Conway, Vancouver ID Centre	Session I: Oral Abstracts: Social Sciences and Community Stockholm/Oslo Chairperson: Jo Neale, King's College London, United Kingdom
1:45 pm - 2:00 pm	Outreach Screening and Treatment for Hepatitis C in a Drug Treatment Unit – An Exploratory Assessment of Feasibility and Cost Effectiveness København Ashley Brown, Imperial College London	Relationships and Injecting Dyads: Identifying Key Interpersonal Factors Underlying Injecting Behaviors and Hepatitis C Virus (Hcv) Transmission among Injecting Partnerships Stockholm/Oslo Meghan Morris, University of California, San Francisco
	Abstract	Abstract
	Presentation	
2:00 pm - 2:15 pm	High Rates of Sustained Virological Response in People Who Inject Drugs Treated with All-Oral Direct Acting Antiviral Regimens København Alain Litwin, Albert Einstein College of Medicine and Montefiore Medical Center	Becoming a Buddy: Accordance and Incompatibility in the Hepatitis C Peer Support Role Stockholm/Oslo Magdalena Harris, London School of Hygiene and Tropical Medicine
	Abstract	Abstract
	Presentation	Presentation
2:15 pm - 2:30 pm	Real World Outcomes of Direct Acting Antiviral (DAA) Therapy for Hepatitis C (HCV) Amongst Persons Who Inject Drugs Treated in an Inner-city Hepatitis C treatment Program, Vancouver, Canada København Mark Hull, BC Centre for Excellence in HIV/AIDS	Qualitative Evaluation of the Decisions and Experiences of People Who Inject Drugs Who Received a Liver Disease Assessment as Part of a Liver Health Promotion Campaign: The Liverlife Study Stockholm/Oslo Alison Marshall, The Kirby Institute

[Abstract](#)

[Presentation](#)

2:30 pm - 2:45 pm

Comparison of Rates of Recurrent HCV Viremia in High-Risk Patients Receiving All-Oral and Interferon-Based Regimens

København

Tyler Raycraft

[Abstract](#)

[Presentation](#)

2:45 pm - 2:50 pm

Treatment Evaluation and Uptake among Persons with Chronic Hepatitis C on Opium Substitution Therapy. Is Treatment as Prevention Realistic?

København

Anne Lindebo Holm Øvrehus, Odense University Hospital

[Abstract](#)

[Presentation](#)

2:50 pm - 2:55 pm

Optimal Adherence during HCV Treatment amongst Active Drug Users at a Community Based Program in Toronto, Canada

København

[Abstract](#)

[Presentation](#)

Qualitative Insights into the Lived Experience of Interferon-Free Treatments

Stockholm/Oslo

David Whiteley, Edinburgh Napier University

[Abstract](#)

[Presentation](#)

The Australian Response and Uptake of the New Subsidised Hepatitis C Direct Acting Anti-Virals among the Community of People Who Inject Drugs

Stockholm/Oslo

Jude Byrne, The Australian Injecting and Illicit Drug users League

[Abstract](#)

Blood Borne Virus Risk Behaviours among People Who Inject Drugs in the UK: A Qualitative Exploration

Stockholm/Oslo

Kate Mason, South Riverdale Community Health Centre

Davina Swan, King's College London

[Abstract](#)

[Abstract](#)

[Presentation](#)

2:55 pm - 3:00 pm

Contingency Management Improves HCV Linkage and Treatment Outcomes in Persons Who Inject Drugs: A Pilot Study

København

Brianna Norton, Montefiore Medical Center

[Abstract](#)

Utilising Social Capital to Promote HCV Treatment in Prison

Stockholm/Oslo

Lise Lafferty, The Kirby Institute, UNSW Australia

[Abstract](#)

[Presentation](#)

3:00 pm - 3:30 pm

Coffee Break

Foyer

3:30 pm - 5:00 pm

Session J: Assessment and Management of HCV Infection

Scandinavia Ballroom

Chairperson: Jason Grebely, The Kirby Institute, UNSW, Australia

3:30 pm - 3:50 pm

Simplified HCV Diagnostics

Scandinavia Ballroom

Teri Roberts, Foundation for Innovative New Diagnostics, Switzerland

[Abstracts](#)

[Presentation](#)

3:50 pm - 4:00 pm

It's Your Liver: Peer to Peer HCV Testing and Education

Scandinavia Ballroom

Bent Arild Stornes, ProLAR, Norway

[Abstract](#)

[Presentation](#)

4:00 pm - 4:20 pm

Liver Disease Assessment Among PWID: The Role of Transient Elastography

Scandinavia Ballroom

Peer Brehm Christensen, University of Southern Denmark, Denmark

[Presentation](#)

4:20 pm - 4:40 pm

HCV Reinfection Following SVR: Clinical and Public Health Implications

Scandinavia Ballroom

Håvard Midgard, Akershus University Hospital, Norway

[Presentation](#)

4:40 pm - 5:00 pm

Understanding Liver Cirrhosis and its Complications

Scandinavia Ballroom

John Willy Haukeland, Oslo University Hospital, Norway

[Abstract](#)

[Presentation](#)

- 5:00 pm **End of Conference Day 2**
Scandinavia Ballroom
- 5:00 pm - 6:00 pm **INHSU General Assembly Members Meeting**
Scandinavia Ballroom
- 7:00 pm - 11:00 pm **Conference Dinner**
Posthallen

09/09/2016 Access and Implementation

8:30 am - 10:00 am **Session K: Parallel Workshops**
No location

8:30 am - 10:00 am	Workshop #1: Getting Involved: Peer Support Skagerak Chairperson: Berne Stålenkrantz, The Swedish Drug Users Union, Sweden	Workshop #2: HCV Prevention: What Works and What Doesn't? København Chairperson: Holly Hagan, New York University, United States Chairperson: Eberhard Schatz	Workshop #3: HCV Testing and Care in Prisons Eidsvoll Chairperson: Andrew Lloyd, University of New South Wales, Australia Chairperson: Pernille Sauer	Workshop #4: Liver Disease Assessment Among PWID: Hands On Stockholm Chairperson: Peer Brehm Christensen, University of Southern Denmark, Denmark Chairperson: Håvard Midgard, Akershus University Hospital, Norway	Workshop #5: The Low Threshold HCV Clinic Bergen Chairperson: John F Dillon, University of Dundee, United Kingdom Chairperson: Leon Wylie	Workshop #6: HCV Epidemiology: Populations, Data Sources and Missing Data Oslo Chairperson: Matthew Hickman, University of Bristol, United Kingdom Chairperson: Gregory Dore, The Kirby Institute, UNSW, Australia Chairperson: Julie Bruneau, Université de Montréal
--------------------	---	---	---	---	---	--

[Abstract](#)

[Abstract](#)

[Abstract](#)

[Abstract](#)

[Abstract](#)

[Presentation](#)

[Presentation](#)

[Abstract](#)

[Presentation](#)

[Presentation](#)

10:00 am - 10:45 am

Coffee Break

Foyer

10:45 am - 12:00 pm

Session L: Novel Models of HCV Care

Scandinavia Ballroom

Chairperson: Gregory Dore, The Kirby Institute, UNSW, Australia

10:45 am - 11:05 am

HCV Treatment in the Prison Setting

Scandinavia Ballroom

Andrew Lloyd, University of New South Wales, Australia

[Abstract](#)

[Presentation](#)

11:05 am - 11:25 am

Pharmacy Based HCV Treatment

Scandinavia Ballroom

John F Dillon, University of Dundee, United Kingdom

[Abstract](#)

[Presentation](#)

11:25 am - 11:40 am

Decentralised HCV Shared Care: The SACC Project

Scandinavia Ballroom
Lars Peters, Rigshospitalet, Denmark

[Abstract](#)

[Presentation](#)

11:40 am - 12:00 pm **New Technologies for Addressing Treatment Barriers and Treatment Adherence**
Scandinavia Ballroom
Jeffrey J Weiss, Mount Sinai Hospital, United States

[Abstract](#)

[Presentation](#)

12:00 pm - 1:30 pm

Lunch

Restaurant

12:15 pm - 1:15 pm

Industry Sponsored Symposium

Scandinavia Ballroom

1:45 pm - 2:45 pm

Session M: Drug Policy

Scandinavia Ballroom

Chairperson: Anya Sarang, Andrey Rylkov Foundation for Health and Social Justice, Russia

Chairperson: Margaret Hellard, Burnet Institute, Australia

1:45 pm - 2:05 pm

War on Drugs or War on Disease?

Scandinavia Ballroom

Ethan Nadelmann, Drug Policy Alliance, United States

2:05 pm - 2:25 pm

Report from United Nations General Assembly Special Session on the World Drug Problem 2016

Scandinavia Ballroom

Daniel Wolfe, Open Society Foundations, United States

[Presentation](#)

2:25 pm - 2:30 pm

HA-REACT: The European Joint Action on HIV and Coinfection Prevention and Harm Reduction - What's in it for Hepatitis?

Scandinavia Ballroom

Jeffrey V Lazarus, Rigshospitalet, University of Copenhagen, Denmark

[Presentation](#)

2:30 pm - 2:50 pm

Can information and communication technologies (ICTs) increase treatment opportunities for people who are homeless and people who inject drugs?

Scandinavia Ballroom

Jo Neale, King's College London, United Kingdom

[Abstract](#)

[Presentation](#)

2:50 pm - 3:00 pm

The INHSU Video Project

Scandinavia Ballroom

Nikki Cavenagh, The Digital Clinic, Australia

3:00 pm - 3:15 pm

Coffee Break

Foyer

3:15 pm - 4:00 pm

Session N: HCV Care in Resource-Limited Countries

Scandinavia Ballroom

Chairperson: Janko Belin, Društvo AREAL, Slovenia

Chairperson: Jeffrey V Lazarus, Rigshospitalet, University of Copenhagen, Denmark

3:15pm - 3:35 pm

The Georgia HCV Elimination Program

Scandinavia Ballroom

Maia Butsashvili, Health Research Union

[Abstract](#)

[Presentation](#)

3:35 pm - 3:55 pm

Russia: Hepatitis C Treatment Gap and Ways Forward

Scandinavia Ballroom

Anya Sarang, Andrey Rylkov Foundation for Health and Social Justice, Russia

[Abstract](#)

3:55 pm - 4:15 pm

[Presentation](#)

Access to DAAs From an Asian Perspective

Scandinavia Ballroom

Giten Khwairakpam, TREAT Asia, Thailand

[Abstract](#)

[Presentation](#)

4:15 pm - 4:25 pm

HCV Infection Among PWID: Research Priorities for Optimizing Prevention, Management and Treatment in the Era of DAAs

Scandinavia Ballroom

Jason Grebely, The Kirby Institute, UNSW, Australia

4:25 pm - 4:30 pm

Conference Closing

Scandinavia Ballroom

4:30 pm

End of Conference

Scandinavia Ballroom